Description
Bosutinib, marketed under the brand name BOSULIF, It is an prescription medication that has been approved bosutinib (Bosulif, Pfizer) for the treatment of chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) on multiple dates:
December 19, 2017
The FDA granted accelerated approval for adults with newly-diagnosed CP Ph+ CML.
September 26, 2023
The FDA approved bosutinib for pediatric patients 1 year of age and older with CP Ph+ CML.
What is BOSULIF (bosutinib) ?
BOSULIF is a kinase inhibitor indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
Source Content From US FDA
How to order approved “BOSULIF (bosutinib) for tablets” Medicine?
BOSULIF (Bosutinib) tablets is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing BOSULIF and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
